WilliamHill¹Ù·½ÍøÕ¾

OAÈë¿Ú
±¨¸æµ¥ÅÌÎÊ
ÔÚÏ߿ͷþ
ÍþÁ®Ï£¶û¡¤williamhill(Öйú)ÖÐÎĹٷ½ÍøÕ¾
ÐÂÎÅÖÐÐÄ
News Center
ÄãÖªµÀÂð£¿ÉíÌå´úлԭÀ´Óиö“Ä»ºóÖ¸»Ó¹Ù”
Ðû²¼£º2026/01/31

½üÄêÀ´ £¬È«Çò·ÊÅÖÖ¢»¼²¡ÂÊÒ»Á¬ÉÏÉý £¬·ÊÅÖ¼°Ïà¹Ø´úл×ÛºÏÕ÷ÏÔÖøÔöÌíÁËÌÇÄò²¡¡¢ÐÄѪ¹Ü¼²²¡µÈ¶àÖÖÂýÐÔ²¡µÄ±¬·¢Î£º¦ ¡£Òò´Ë £¬Ö¬·¾×éÖ¯×÷ΪÈËÌåÖ÷ÒªÄÚÉøÍ¸Æ÷¹Ù £¬Æä¹¦Ð§×´Ì¬±¸ÊܹØ×¢ ¡£Ïà¹ØÑо¿·¢Ã÷ £¬Ö¬ÁªËØÊÇÖ¬·¾×éÖ¯ÌØÒìÐÔÉøÍ¸µÄÒªº¦Ï¸°ûÒò×Ó £¬ÑªÒºÖÐÖ¬ÁªËØË®Æ½µÄת±ä £¬ÓÌÈçѸËٵġ°¾¯±¨Æ÷¡± £¬ÄÜΪÎÒÃÇÕ¹ÏÖ¶àÖÖÂýÐÔ¼²²¡µÄDZÔÚΣº¦ºÍÉú³¤×´Ì¬ ¡£


ʲôÊÇÖ¬ÁªËØ£¿


Ö¬ÁªËØ£¨ADPN£©ÊÇÓÉÖ¬·¾Ï¸°ûÉøÍ¸µÄÄÚÔ´ÐÔÉúÎï»îÐÔ¶àëÄ»òÂѰ×ÖÊ £¬ÔÚÉíÌå´úлÖÐÊÎÑÝ×ÅÖÁ¹ØÖ÷ÒªµÄ½ÇÉ« £¬Ö÷Òª×÷ÓÃÓÚ¸ÎÔࡢѪ¹ÜºÍÒÈÏÙµÈ×éÖ¯ £¬Ê©Õ¹ÒȵºËØÔöÃô¡¢½µÑªÌǺͿ¹Ñ×µÈÒªº¦µ÷Àí×÷Óà £¬ÊÇÒ»Öֶ๦Чµ÷Àí¼Á£Û1-2£Ý ¡£


Ö¬ÁªËØÓë³£¼û¼²²¡µÄ¹ØÁª

1.·ÊÅÖ


Ö¬ÁªËØÊÇÏÖÔÚÒÑÖªÓë·ÊÅֳʸºÏà¹ØµÄϸ°ûÒò×Ó ¡£³¬ÖØ·ÊÅÖ»¼ÕßµÄÖ¬·¾Ñõ»¯¹¦Ð§½ÏÈõ £¬ÌÇ´úл¹¦Ð§¼õÍË £¬Í¬Ê±»¹ÃæÁÙ×ÅÑ×Ö¢¼°¶¯ÂöÖàÑùÓ²»¯µÄΣº¦ £¬Ö÷ÒªÊÇÆäÌåÄÚÖ¬ÁªËØË®Æ½µÍÓÚÕý³£ÌåÖÊÁ¿ÈËȺ £¬µ¼ÖÂÖ¬ÁªËØÎÞ·¨³ä·ÖÑéÕ¹×÷ÓãÛ6-7£Ý ¡£


ͬʱ £¬Indulekha K¡¢Surendar J¡¢Anjana R MµÈÓ¡¶ÈѧÕߣÛ8£ÝÑо¿Ö¤Êµ £¬Ö¬ÁªËØÓë·ÊÅÖÈËȺµÄ´úл״̬Ç×½üÏà¹Ø,µÍÖ¬ÁªËØË®Æ½»áÔöÌí·ÊÅÖÈËȺ·ºÆð´úлÒì³£¡¢¸ßѪѹ¼°¸ßÈýõ£¸ÊÓÍѪ֢µÄΣº¦ ¡£Ö¬ÁªËØ¿Éͨ¹ýÓÕµ¼Ñªáú½éÃܶÈÖ¬ÂѰ׵¨¹Ì´¼£¨HDL-C£©Éý¸ß¡¢¸ÊÓÍÈýõ¥£¨TG£©ïÔÌ­À´¸ÄÉÆÖ¬´úл £¬»¹¿Éͨ¹ý»Ö¸´Ö¬·¾×éÖ¯ÉøÍ¸Ö¬ÁªËصÄÄÜÁ¦ £¬¾ÀÕý´úлÔÓÂÒ £¬½ø¶ø½µµÍ·ÊÅÖÏà¹ØÂýÐÔ²¡µÄ·¢²¡Î£º¦£Û9£Ý ¡£


2.ÌÇÄò²¡


´ó×ÚÑо¿Ö¤Êµ £¬ÌÇÄò²¡·¢²¡Î£º¦ÓëÖ¬ÁªËØË®Æ½³ÊÏÔÖø¸ºÏà¹Ø ¡£Ö¬ÁªËØÖ÷Ҫͨ¹ýÌá¸ßÒȵºËØÃô¸ÐÐÔ £¬ÔöÇ¿ÒȵºËØÒÖÖÆÌÇÔ­ÒìÉúµÄ×÷Óà £¬ÒÖÖÆ¸ÎÌÇÔ­ÌìÉú £¬ÊÇά³Ö»úÌåѪ֬ѪÌÇÎȹ̵ÄÖ÷Òªµ÷ÀíÒò×Ó ¡£


1770860043590851.png


Ö¬ÁªËØË®Æ½½µµÍ»á¼Ó¾çÒȵºËضԿ¹ £¬Éý¸ßÌÇÄò²¡Î£º¦ £¬¸üΪҪº¦µÄÊÇ £¬Ö¬ÁªËØË®Æ½µÄת±äÍùÍùÔçÓÚѪÌÇÉý¸ß £¬ÊÇÌÇÄò²¡±¬·¢µÄÖ÷ÒªÔçÆÚÔ¤¾¯ÐźÅÖ®Ò» ¡£Òò´Ë £¬Ö¬ÁªËØ¿É×÷Ϊ·¢Ã÷¡¢Õï¶Ï2ÐÍÌÇÄò² ¡£¨T2DM£©¸ßΣº¦¸öÌå¼°¼à²â¼²²¡Ï£ÍûµÄÖ¸±ê£Û2-3£Ý ¡£


1770860055599491.png

Ö¬ÁªËØÕ¹ÍûÌÇÄò²¡Î£º¦¿µ½¡¹ÜÀí½¨Òé


3.ÐÄѪ¹Ü¼²²¡


Ö¬ÁªËؾßÓп¹¶¯ÂöÖàÑùÓ²»¯¡¢¿¹¸ßѪÌǼ°¿¹Ñ×Ö¢µÈ¶àÖÖ×÷Óà £¬ÓÚ´úл¼°¶¯ÂöÖàÑùÓ²»¯Àú³ÌÒâÒåÖØ´ó £¬ÊÇÆÀ¹ÀÐÄѪ¹Ü¼²²¡Î£º¦µÄÐÂÐ˱ê¼ÇÎïÖ®Ò» ¡£


¶¯ÂöÖàÑùÓ²»¯ÊÇÐÄѪ¹Ü¼²²¡µÄÖ÷Òª²¡Àí»ù´¡ £¬µ±Ö¬ÁªËØÈ±·¦Ê± £¬Ñª¹ÜÄڱڵġ°±£»¤Ä¤¡±»á±ä±¡ £¬¸üÒ×ÊÜË𠣬µ¼Ö°߿éÐÎ³ÉºÍÆÆËé £¬ÔöÌíÐ£ËÀ¡¢ÖзçµÈÐÄѪ¹ÜÊÂÎñµÄ±¬·¢Î£º¦ ¡£Ïà¹ØÑо¿·¢Ã÷ £¬¼±ÐÔÐ£ËÀ£¨AMI£©»¼ÕßѪÇåÖ¬ÁªËØË®Æ½»áϽµ £¬¸Ãת±äÓë²»Á¼Ô¤ºóÏà¹Ø £¬ÊÇÕ¹ÍûAMIºó±¬·¢ÐÄÁ¦Ë¥½ß£¨HF£©¼°Ö÷Òª²»Á¼ÐÄѪ¹ÜÊÂÎñ£¨MACE£©µÄÓмÛÖµÖ¸±ê£Û4£Ý ¡£¾Ýͳ¼Æ £¬¼±ÐÔAMI»¼Õß½ÓÊܾ­Æ¤¹Ú×´¶¯Âö½éÈëÊõ£¨PCI£©ºó2¡¢3ÄêµÄMACE±¬·¢ÂÊ»®·ÖΪ16%ºÍ20%£Û5£Ý £¬¿É¼û £¬ÑªÇåÖ¬ÁªËØÕ¹ÍûHFºÍMACEµÄ¼ÛÖµÏÔÖø ¡£


4.·Ç¾Æ¾«ÐÔÖ¬·¾¸Î


·Ç¾Æ¾«ÐÔÖ¬·¾¸Î² ¡£¨NAFLD£©ÊÇÒÔ¸Îϸ°ûÖ¬·¾³Á»ý¡¢±äÐÔΪ²¡ÀíÌØÕ÷µÄ³£¼ûÂýÐԸβ¡ ¡£Ïà¹ØÊý¾ÝÏÔʾ£Û10£Ý £¬È«ÇòNAFLDÊ¢ÐÐÂÊ´ï30% £¬ÇÒÈÔÔÚÒ»Á¬ÉÏÉý ¡£ÓÐÎÄÏ×Ö¸³ö£Û11£Ý £¬µÍÖ¬ÁªËØÑªÖ¢¿ÉÄÜÔÚNAFLDÏò·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎÑ×Ï£ÍûµÄÀú³ÌÖÐʩչÖ÷Òª×÷Óà £¬ÓÐÍû³ÉΪδÀ´NAFLDÕïÁƵÄDZÔÚÊÓ²ìµã ¡£ÑªÇåµÍÖ¬ÁªËØË®Æ½ÓëNAFLD±¬·¢¼°ÌÇÖ¬´úл¡¢¸Î¹¦Ð§Òì³£Ïà¹Ø £¬¿É×÷ΪNAFLDDZÔÚÕ¹ÍûÖ¸±ê £¬µ«Ïà¹Ø½áÂÛÈÔÐè½øÒ»²½Ñо¿ÑéÖ¤ ¡£


5.¶àÄÒÂѳ²×ÛºÏÕ÷


¼ÈÍùÑо¿Åú×¢ £¬¶àÄÒÂѳ²×ÛºÏÕ÷(PCOS)»¼ÕßµÄѪÇåÄòËáˮƽ¸ßÓÚ·ÇPCOS»¼ÕߣÛ12£Ý,¶øÑªÇåÖ¬ÁªËØË®Æ½ÔòÏà¶Ô½µµÍ ¡£ÄòËá×÷ΪàÑßÊ´úлµÄÖÕ²úÆ·ÓëÖ¬ÁªËسʸºÏà¹Ø ¡£Ö¬ÁªËؾßÓÐÒȵºËØÑù×÷Óà £¬Äܹ»µ÷¿ØÈËÌåÄÚµÄÄÜÁ¿Æ½ºâ £¬Æäˮƽת±äÔÚPCOSµÄ±¬·¢Éú³¤Öб¬·¢Ö÷ÒªÓ°Ïì ¡£PCOSÊÇÓýÁäÆÚÅ®ÐÔ³£¼ûµÄÉúÖ³ÄÚÉøÍ¸´úлÒì³£¼²²¡ £¬Æä±¬·¢Éú³¤µÄϸ°û·Ö×Óѧ»úÖÆÉÐδÍêÈ«ÆÊÎö ¡£Ñ­»·ÑªÖÐÖ¬ÁªËØË®Æ½½µµÍÊÇPCOS»¼Õß³£¼ûµÄ´úлÒì³£ÌåÏÖ £¬Òò´Ë £¬¼ì²âÖ¬ÁªËØË®Æ½¹ØÓÚPCOSµÄÔçÆÚÔ¤·ÀºÍÖÎÁƾßÓÐÖ÷ÒªÒâÒå£Û13£Ý ¡£


ÁÙ´²³£¼ûµÄÖ¬ÁªËØÎÊÌâ½â´ð


Q£ºÄÜͨ¹ý¼ì²âÖ¬ÁªËØË®Æ½À´ÅжÏÉíÌ念½¡×´Ì¬Âð£¿

A£º¿ÉÒÔ×÷Ϊ²Î¿¼ÐÅÏ¢ ¡£ÑªÒºÖеÄÖ¬ÁªËØ£¨ÓÈÆä¸ß·Ö×ÓÁ¿ÑÇÐÍ£©¿É×÷Ϊ´úл¿µ½¡µÄÉúÎï±ê¼ÇÎï £¬µÍÖ¬ÁªËØÍ¨³£ÌáÐÑ2ÐÍÌÇÄò²¡¡¢ÐÄѪ¹Ü¼²²¡µÄ·¢²¡Î£º¦½Ï¸ß ¡£µ«¼ì²âЧ¹ûÐèÍŽáÆäËûÖ¸±ê×ÛºÏÅжÏ £¬²»¿Éµ¥¶À×÷Ϊ¿µ½¡×´Ì¬µÄΨһÆÀÅÐÒÀ¾Ý ¡£


Q£ºÍ¨Ë×ÈËÐèÒª¼ì²âÖ¬ÁªËØË®Æ½Âð£¿

A£ºÒ»Ñùƽ³£ÈËȺ¿É½«Ö¬ÁªËؼì²âÄÉÈëͨÀýÌå¼ì £¬ÓÃÓÚÆÀ¹À×ÔÉí´úл¿µ½¡×´Ì¬ ¡£ÌØÊâ¹ØÓÚ·ÊÅÖ¡¢ÌÇÄò²¡¸ßΣÈËȺ£¨ÈôÓмÒ×åÊ·¡¢¿Õ¸¹ÑªÌÇÆ«¸ßÕߣ©ÒÔ¼°ÐÄѪ¹Ü¼²²¡»¼Õß¶øÑÔ £¬¼ì²âÖ¬ÁªËؿɸ¨ÖúÆÀ¹À´úлΣº¦ £¬ÎªÂýÐÔ¼²²¡µÄ¸ÉÔ¤Ìṩ²Î¿¼ÒÀ¾Ý ¡£


Q£ºµÍÖ¬ÁªËØË®Æ½ £¬Ò»¶¨Òâζ×Å·ºÆðÁË¿µ½¡ÎÊÌâÂð£¿

A£º·×Æç¶¨ ¡£Ö¬ÁªËØË®Æ½ÊܶàÖÖÒòËØÓ°Ïì £¬ÈçÄêËê¡¢ÐÔ±ð¡¢Ô˶¯Ï°¹ßµÈ ¡£µ¥´Î¼ì²âÆ«µÍʱ £¬ÐèÍŽáÌåÖØ¡¢ÑªÌÇ¡¢ÑªÖ¬µÈÖ¸±ê×ÛºÏÅжÏ ¡£ÈôÅãͬÒȵºËضԿ¹¡¢Ö¬·¾¸ÎµÈÎÊÌâ £¬ÔòÐèСÐÄ´úлÒì³£µÄ¿ÉÄÜ ¡£


Q£ºÉíÌå״̬½ÏΪÏûÊݵÄÈËȺ £¬»á²»»áÓÐÖ¬ÁªËØË®Æ½½ÏµÍµÄÇéÐΣ¿

A£º¿ÉÄÜ»á ¡£ËäȻ֬ÁªËØÓëÌåÖ¬³Ê¸ºÏà¹Ø £¬µ«²¿·ÖÊÝÈËȺÌåÓÉÓÚÒÅ´«ÒòËØ¡¢ÂýÐÔѹÁ¦»ò²»Á¼ÉúÑÄϰ¹ß£¨Èç¾Ã×ø²»¶¯¡¢ÓªÑø²»Á¼µÈ£© £¬Ò²¿ÉÄÜ·ºÆðÖ¬ÁªËØË®Æ½Æ«µÍµÄÇéÐÎ £¬½ø¶ø±£´æ´úлΣº¦£¨ÈçÊÝËØ¶Ô¿¹£© ¡£


Q£ºÖ¬ÁªËØË®Æ½¸ß £¬ÉíÌå¾ÍÒ»¶¨¿µ½¡Âð£¿

A£º·×Æç¶¨ ¡£ÉÙÉÙÊýÇéÐÎÏ£¨ÈçÑÏÖØ¼²²¡ÏûºÄ״̬£© £¬Ö¬ÁªËØË®Æ½¿ÉÄÜÒì³£Éý¸ß £¬ÐèÍŽáСÎÒ˽¼ÒÕûÌ念½¡×´Ì¬ÅжÏ £¬²¢·ÇÖ¬ÁªËØË®Æ½Ô½¸ßÔ½ºÃ ¡£


Q£ºÖ¬ÁªËØË®Æ½»áËæ×ÅÄêËêµÄÔöÌí¶ø×ª±äÂð£¿

A£ºÓпÉÄÜ ¡£Ëæ×ÅÄêËêÔöÌí £¬ÈËÌåÖ¬ÁªËØË®Æ½¿ÉÄÜ·ºÆð²¨¶¯ £¬²¿·ÖÖÐÍíÄêÈ˵ÄÖ¬ÁªËØË®Æ½Æ«µÍ £¬ÕâÓë´úлÄÜÁ¦Ï½µÓйØ ¡£¼ÍÂÉÔ˶¯ÓÐÖúÓÚά³ÖÖ¬ÁªËØË®Æ½µÄÎȹÌ ¡£


Q£ºËØÊ³ÕßÉíÌåÄÚµÄÖ¬ÁªËØË®Æ½¸ü¸ßÂð£¿

A£º·×Æç¶¨ ¡£²¿·ÖÑо¿ÏÔʾ £¬ºÏÀíËØÊ³¿ÉÄÜÓÐÖúÓÚά³Ö½Ï¸ßµÄÖ¬ÁªËØË®Æ½ £¬Õâ¿ÉÄÜÓëËØÊ³ÒûʳÖи»º¬ÉÅʳÏËά¡¢²»±¥ºÍÖ¬·¾Ëá¡¢¿¹Ñõ»¯ÎïÖʵÈÒòËØÓйØ £¬ÕâЩÒòËØÓÐÖúÓÚ¸ÄÉÆ´úл״̬ £¬¼ä½ÓÔö½øÖ¬ÁªËصĺϳÉÓëÉøÍ¸ ¡£µ«ÕâÒ»½áÂÛµÄÌõ¼þÊÇ¡°ÓªÑøÆ½ºâ¡±µÄËØÊ³ £¬¶ø·Ç´¿´â¡°²»³ÔÈ⡱µÄÒûʳģʽ ¡£


Q£ºÔÐÆÚ £¬Ôи¾ÌåÄÚµÄÖ¬ÁªËØË®Æ½»áת±äÂð£¿

A£ºÔ­ÔòÉÏ»á ¡£Ö¬ÁªËØË®Æ½ÔÚÔÐÆÚ¿ÉÄÜ·ºÆð²¨¶¯ £¬ÓÈÆäÔÚÔÐÍíÆÚ¿ÉÄÜ»áϽµ ¡£ÔÐÔçÆÚÖÁÖÐÆÚÏà¶ÔÎȹÌ £¬ÀûÓÚά³ÖĸÌå´úлƽºâ¼°Ì¥¶ùÓªÑø¹©Ó¦ £¬¶øµ½ÁËÔÐÍíÆÚ £¬Ëæ×ÅÌ¥¶ù¿ìËÙÉú³¤¡¢Ä¸ÌåÖ¬·¾´¢±¸ÔöÌíÒÔ¼°¼¤ËØË®Æ½£¨Èç´Æ¼¤ËØ¡¢Ôм¤ËØ£©µÄÏÔÖø×ª±ä £¬Ö¬ÁªËØË®Æ½ÍùÍù»á·ºÆðϽµ ¡£


ÕâЩÇéÐÎÓëÈÑÉï´úлÐèÇóÏà¹Ø £¬µ«Ðè×¢ÖØ £¬ÈôÔÐÆÚÖ¬ÁªËØË®Æ½Òì³£¹ýµÍ£¨ÈçÅãͬ·ÊÅÖ»òÈÑÉïÌÇÄò² ¡£© £¬¿ÉÄܼÓÖØÒȵºËضԿ¹ £¬ÔöÌíÈÑÉï²¢·¢Ö¢Î£º¦ £¬Ðèͨ¹ýºÏÀíÒûʳºÍÊʶÈÔ˶¯¾ÙÐе÷¿Ø ¡£


Ö¬ÁªËؼì²âΪ´úл¿µ½¡ÆÀ¹À¿ª·¢ÐÂ;¾¶ £¬ÊÇÆÀ¹ÀÒȵºËØÃô¸ÐÐÔÓëѪ¹Ü±£»¤¹¦Ð§µÄÒªº¦±ê¼ÇÎï £¬ÔÚÕ¹ÍûÌÇÄò²¡¡¢ÐÄѪ¹Ü¼²²¡Î£º¦ £¬ÆÀ¹À·ÊÅÖ¼°Ö¬·¾¸Î´úлΣº¦ £¬¼à²â¸ÉԤЧ¹ûµÈ·½Ãæ¼ÛÖµÏÔÖø £¬¿ÉΪ¸ßΣÈËȺ¼°´úлÐÔ¼²²¡»¼ÕßÌṩÔö²¹ÕïÁÆÐÅÏ¢ £¬Ö§³Ö¾«×¼¿µ½¡¹ÜÀíÓë¼²²¡·ÀÖÎ ¡£


²Î¿¼ÎÄÏ×

£Û1£ÝSTRAUB L G,SCHERER P E£®Metabolic messengers£ºadiponectin[J].Nature Metabolism £¬2019 £¬1(3):334.

£Û2£ÝºØË¼Ë¼,Ëïºèåû,ÕÅÏþÌì £¬µÈ.Ö¬ÁªËؼì²âÔÚ2ÐÍÌÇÄò²¡ÕïÖÎÖеÄÑо¿Ï£Íû[J].ÖйúʵÑéÕï¶Ïѧ,2023,27(11):1374-1377.

£Û3£ÝWANG Y,KOH W P,SIM X £¬et al.Multiple biomarkers improved prediction for the risk of type 2 diabetes mellitus in Singapore Chinese men and women.[J].Diabetes & Metabolism Journal £¬2020 £¬44(2):295.

£Û4£Ý³ÌÔÆÌÎ,Ñî¹âϼ,ÝþÔ¾¶° £¬µÈ.ÄòËáºÍÖ¬ÁªËØÓë¼±ÐÔÐ£ËÀ»¼ÕßÑ×ÐÔÒò×Óˮƽ¼°½éÈëÖÎÁƺ󱬷¢ÐÄÁ¦Ë¥½ßµÄ¹ØÏµ[J].ÖлªÍíÄêÐÄÄÔѪ¹Ü²¡ÔÓÖ¾,2023,25(7):704-707.

£Û5£ÝZHU Y £¬ZHANG J L £¬YAN X J £¬et al.Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention[J].Cardiovasc Diabetol £¬2022 £¬21(1):186.

£Û6£ÝÂíÇ¿.IP6K1ÔÚ³¬ÖØ/·ÊÅÖÈËȺºÍ3T3L1ϸ°ûÖÐÓëÖ¬ÁªËصÄÏà¹ØÐÔ¼°Æä»úÖÆÑо¿[D].¹ãÖÝÄÏ·½Ò½¿Æ´óѧ,2019.

£Û7£ÝÕÅÓ굤 £¬ÁõÊËȺ £¬·¶´æÏ¼ £¬µÈ.ÒȸßѪÌÇËØÑùëÄ1ÊÜÌ弤¶¯¼Á¶Ô2ÐÍÌÇÄò²¡ºÏ²¢³¬ÖØ/·ÊÅÖ»¼Õß²î±ð²¿Î»Ö¬·¾ÂþÑܼ°¼¡È⺬Á¿µÄÓ°Ïì[J].ÄÏ·½Ò½¿Æ´óѧѧ±¨,2019 £¬39(4)£º450-455.

£Û8£ÝIndulekha K,Surendar J,Anjana R M,et al.Metabolic obesity,adipocytokine-s,and inflammatory markers in Asian Indians¡ªCURES-124[J].Diabetes Technol Th-er,2015 £¬17(2)£º134-141.

£Û9£Ý³ÂÙ»éª £¬ÎéÀö £¬ÖìÒæÃñ £¬µÈ.·ÊÅÖÕßѪÇåÖ¬ÁªËØË®Æ½Óë´úл״̬µÄ¹ØÏµ[J].»ªÖпƼ¼´óѧѧ±¨£¨Ò½Ñ§°æ£©,2021 £¬50(6)£º778-782.

£Û10£ÝYounossi ZM,Golabi P,Paik JM,et al.The global epidemiology of nonalcohol-ic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH):a systematic review[J].Hepatology,2023 £¬77(4)£º1335-1347.

£Û11£ÝMavilia MG,Wu GY.Liver and serum adiponectin levels in nonalcoholic fatty liver disease[J].J Dig Dis,2021 £¬22(4)£º214-221.

£Û12£ÝGozukara IO, Gozukara KH,Kucur SK,et al.Association of Glomerular Filtration Rate with Inflammation in Polycystic Ovary Syndrome.[J].Int J Fertil Steril,2015 £¬9£º176-182.

£Û13£ÝÇdz̳Ì £¬Éòɽ÷.¶àÄÒÂѳ²×ÛºÏÕ÷»¼ÕßÄòËáÓëÖ¬ÁªËØÏà¹ØÐÔ×ÛÊö[J]. ÖйúÉúÓý¿µ½¡ÔÓÖ¾,2021 £¬32(4)£º399-401.



ÍøÕ¾µØÍ¼